Cellectar Biosciences (CLRB) Competitors $5.15 +0.07 (+1.38%) Closing price 04:00 PM EasternExtended Trading$5.16 +0.01 (+0.29%) As of 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLRB vs. MNOV, GANX, ABVC, IMMX, HOWL, BTAI, CLNN, CUE, DTIL, and DRRXShould you be buying Cellectar Biosciences stock or one of its competitors? The main competitors of Cellectar Biosciences include MediciNova (MNOV), Gain Therapeutics (GANX), ABVC BioPharma (ABVC), Immix Biopharma (IMMX), Werewolf Therapeutics (HOWL), BioXcel Therapeutics (BTAI), Clene (CLNN), Cue Biopharma (CUE), Precision BioSciences (DTIL), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry. Cellectar Biosciences vs. Its Competitors MediciNova Gain Therapeutics ABVC BioPharma Immix Biopharma Werewolf Therapeutics BioXcel Therapeutics Clene Cue Biopharma Precision BioSciences DURECT MediciNova (NASDAQ:MNOV) and Cellectar Biosciences (NASDAQ:CLRB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Do institutionals and insiders believe in MNOV or CLRB? 9.9% of MediciNova shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 13.6% of MediciNova shares are held by insiders. Comparatively, 5.0% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate MNOV or CLRB? MediciNova currently has a consensus price target of $7.00, indicating a potential upside of 464.52%. Cellectar Biosciences has a consensus price target of $375.00, indicating a potential upside of 7,181.55%. Given Cellectar Biosciences' higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than MediciNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00Cellectar Biosciences 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is MNOV or CLRB more profitable? MediciNova's return on equity of -23.12% beat Cellectar Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets MediciNovaN/A -23.12% -21.85% Cellectar Biosciences N/A -486.67%-150.57% Which has stronger earnings & valuation, MNOV or CLRB? MediciNova has higher revenue and earnings than Cellectar Biosciences. MediciNova is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediciNova$1MN/A-$11.04M-$0.25-4.96Cellectar BiosciencesN/AN/A-$44.58M-$19.91-0.26 Which has more risk and volatility, MNOV or CLRB? MediciNova has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Does the media favor MNOV or CLRB? In the previous week, Cellectar Biosciences had 1 more articles in the media than MediciNova. MarketBeat recorded 5 mentions for Cellectar Biosciences and 4 mentions for MediciNova. MediciNova's average media sentiment score of 0.98 beat Cellectar Biosciences' score of 0.98 indicating that MediciNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cellectar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMediciNova beats Cellectar Biosciences on 9 of the 15 factors compared between the two stocks. Get Cellectar Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLRB vs. The Competition Export to ExcelMetricCellectar BiosciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.22M$10.84B$5.79B$10.18BDividend YieldN/A1.86%5.73%4.61%P/E Ratio-0.2620.5674.8626.40Price / SalesN/A30.45543.29125.95Price / CashN/A25.0025.8129.91Price / Book0.573.4313.256.28Net Income-$44.58M$210.63M$3.29B$270.38M7 Day Performance2.39%-0.87%0.47%2.70%1 Month Performance18.66%1.65%4.60%5.99%1 Year Performance-91.94%-11.60%73.42%25.94% Cellectar Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLRBCellectar Biosciences3.5144 of 5 stars$5.15+1.4%$375.00+7,181.6%-92.1%$16.22MN/A-0.2610Short Interest ↓MNOVMediciNova2.1633 of 5 stars$1.26-2.3%$7.00+455.6%-32.4%$63.27M$134.60K-5.0410GANXGain Therapeutics2.9308 of 5 stars$1.75-0.6%$8.00+357.1%+13.3%$63.27M$50K-2.7820Positive NewsGap UpABVCABVC BioPharma0.6871 of 5 stars$2.72+2.6%N/A+310.6%$62.39M$510K-16.0030IMMXImmix Biopharma3.0898 of 5 stars$2.17+0.9%$7.00+222.6%+12.9%$61.99MN/A-2.829News CoveragePositive NewsAnalyst ForecastShort Interest ↑HOWLWerewolf Therapeutics4.0065 of 5 stars$1.33-1.5%$8.00+501.5%-38.9%$61.73M$1.88M-0.8140BTAIBioXcel Therapeutics3.9572 of 5 stars$4.23+11.6%$39.75+839.7%-71.4%$60.67M$2.27M-0.3390Analyst ForecastShort Interest ↑Gap DownCLNNClene3.1602 of 5 stars$6.63+10.0%$33.00+397.7%-13.9%$60.24M$340K-1.76100Gap UpHigh Trading VolumeCUECue Biopharma2.4515 of 5 stars$0.78-0.4%N/A+25.9%$59.94M$9.29M-1.3960Positive NewsDTILPrecision BioSciences4.094 of 5 stars$4.97-2.0%$47.00+845.7%-55.2%$59.76M$68.70M-0.56200DRRXDURECT1.5165 of 5 stars$1.96+2.6%N/AN/A$59.31M$2.03M-19.6080Short Interest ↓ Related Companies and Tools Related Companies MNOV Alternatives GANX Alternatives ABVC Alternatives IMMX Alternatives HOWL Alternatives BTAI Alternatives CLNN Alternatives CUE Alternatives DTIL Alternatives DRRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLRB) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
